| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5615279 | Journal of Clinical Lipidology | 2016 | 10 Pages |
Abstract
Long-term mipomersen treatment was successful regarding efficacy parameters for pediatric HoFH patients. The safety profile was consistent with other phase 3 clinical trials. Long-term compliance was an issue. Measures supporting adherence should be encouraged.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Frederick J. PhD, Marjet J. MD, PhD, Sheryl L. PharmD, Charlotte H. MA, John J. MD, PhD,